Scribe Therapeutics is the latest biotech to prepare a public listing, as the company looks to propel its lipid-lowering medicines through clinical trials. While the Bay Area biotech has yet to set ...

A month after Genentech confirmed the restructuring of its early development group, the Roche subsidiary has now disclosed ...

Novartis is pushing deeper into antibody-drug conjugate (ADC) development, paying $1.1 billion upfront to buy Myricx Bio for a pipeline based on a novel payload. Switzerland’s Novartis largely stayed ...

The Fosun subsidiary is paying the upfront fee, committing up to 1.12 billion yuan ($166 million) in milestones and agreeing ...

Roche’s investigational KRAS G12C inhibitor has beaten Amgen’s Lumakras and Bristol Myers Squibb’s Krazati in a phase 3 trial ...

Despite decades of scientific progress and billions of dollars invested in oncology research, metastatic cancer remains overwhelmingly incurable. While many therapies can delay disease progression and ...

QuantumCell has licensed AlzeCure Pharma’s Alzheimer’s disease platform and lead asset for $12 million upfront in a heavily back-loaded deal that bags a potentially symptom-relieving drug candidate on ...

Roche may have failed to buy out Illumina back in 2012, but now it’s trying to take up some of the gene sequencing specialist ...

When writing a blockbuster movie script, screenplay writers are sure to include all the essential elements of a hit | The ...

Insilico Medicine has signed a deal worth up to $600 million with Takeda to collaborate on asset discovery across the Japan Big Pharma's therapeutic areas of interest.  | Insilico Medicine has signed ...

Five months after Corxel Pharmaceuticals reeled in hundreds of millions of dollars to support further development of its oral ...

The FDA has sent an End of Enforcement notice to consumer wearable device company Whoop, putting a formal end to the agency’s ...